Specifically, In GBM, HNSC, LGG, LUAD, LUSC, PCPG, and TGCT, high PLEK2 expression correlated with higher TIDE scores, suggesting these patients may derive less benefit from immunotherapy. This evidence concerns the gene PLEK2 and glioblastoma.